Quick Answer
Galera Therapeutics, Inc. reported Stockholders Equity of $3.97 million for the year ending 2025.
- Galera Therapeutics, Inc. showed an increase of +102.7% in Stockholders Equity from 2024 to 2025.
- This data is from Galera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$82.63 million | Q2 2018: -$87.94 million | Q3 2018: -$94.44 million | Q1 2019: -$116.67 million | Q2 2019: -$129.66 million | Q3 2019: -$144.62 million | Q1 2020: $53.06 million | Q2 2020: $40.24 million | Q3 2020: $24.70 million | Q1 2021: -$10.57 million | Q2 2021: -$25.52 million | Q3 2021: -$43.17 million | Q1 2022: -$70.47 million | Q2 2022: -$83.25 million | Q3 2022: -$97.50 million | Q1 2023: -$97.61 million | Q2 2023: -$115.00 million | Q3 2023: -$126.55 million | Q1 2024: -$134.69 million | Q2 2024: -$138.03 million | Q3 2024: -$143.06 million | Q1 2025: -$147.23 million | Q2 2025: -$147.95 million | Q3 2025: -$149.22 million.
- Over the full 9 years of available data (2017 to 2025), Galera Therapeutics, Inc.'s Stockholders Equity has grown by 105.2%.
- Historical annual values: Fiscal year 2025: $3.97 million | Fiscal year 2024: -$148.04 million | Fiscal year 2023: -$131.19 million | Fiscal year 2022: -$109.18 million | Fiscal year 2021: -$58.00 million | Fiscal year 2020: $6.12 million | Fiscal year 2019: $69.61 million | Fiscal year 2018: -$104.82 million | Fiscal year 2017: -$76.11 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: